BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

InspireMD Ltd. Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry


9/23/2009 10:49:01 AM

SAN FRANCISCO, September 23 /PRNewswire/ -- InspireMD, developers of MGuard(TM), announced today that the first patient has been enrolled in the Israeli MGuard(TM) Registry. MGuard(TM) was successfully implanted in Natanya, Israel, at the Laniado Hospital Cath Lab, managed by Dr. Yitzhak Herz, the principal investigator for the Registry at this hospital.

The Israeli MGuard Registry will enroll 100 'real world' MGuard patients from eight hospitals in Israel. Data from the registry will be used to support data from other MGuard clinical studies.

The first MGuard Stent in the Israeli MGuard Registry was implanted by Dr. Guy Schoenmann from the Laniado Hospital in Netanya. The patient was a 70 year old male treated for myocardial infarction (MI) caused by a thrombus occluding the right coronary artery. Dr. Schoenmann stated: "MGuard(TM) was delivered with no complications and it immediately enabled excellent flow in the artery. We experienced a very successful procedure and I am very pleased that MGuard is now available to us on daily basis".

Mr. Eli Bar CTO and VP R&D stated: "Currently MGuard is mostly used in AMI, SVG, and thrombus containing lesions. The Israeli MGuard registry is very important for us in order to understand the clinical performance of MGuard in the 'real world' and receive a wider perspective on its use in special patient subgroups".

On September 24th 2009, InspireMD will Sponsor a Breakfast Meeting at the TCT Conference 2009 in San Francisco, Titled "The Role of the MGuard(TM) Stent in Thrombus Management During AMI Interventions". The meeting chairman will be Dr. Martin B. Leon , the Chairman of the CRF, NY; Associate Director at New York Presbyterian Hospital and Professor at Columbia University Medical Center NY. InspireMD's Breakfast Meeting faculty will include Alexandre Abizaid, MD, PhD, Antonio Colombo, MD, Peter J. Fitzgerald, MD, PhD, Jacek Legutko, MD, PhD, Chaim Lotan MD and Christian M. Spaulding, MD, PhD. At the meeting the latest MAGICAL STEMI clinical data will be presented as well as MGuard(TM) in ACS - Data from the Brazilian INSPIRE trial.

About MGuard(TM) Coronary

MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The protective sleeve is composed of a micron-level-fiber which is knit in order to ensure flexibility while retaining the strength characteristics of the fiber material. The sleeve is designed to expand seamlessly when the stent is deployed, without affecting the structural integrity of the stent. The MGuard(TM) coronary stent provides permanent embolic protection, without complicating deliverability. Reduced injury to the vessel as a result of diffused stent pressure is a benefit of the sleeve which may lead to lower risk of restenosis. MGuard(TM) is CE Mark approved.

The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.

About InspireMD

InspireMD Ltd. is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis.

In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures. For further information visit http://www.inspire-md.com

SOURCE InspireMD

CONTACT: Contact: Jonina Ohayon, Marketing Director, Tel +972-52-5791120,
jonina@inspire-md.com .



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES